Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
September 02, 2014 at 08:04 AM EDT
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative ...